Dataset Information


OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.

ABSTRACT: Immunotherapy has shown promising results in cancer treatment. Research shows that most patients might be resistant to these therapies. So, new immune therapies are needed. OX40 (CD134) and OX40 ligand (OX40L), costimulatory molecules, express on different types of immune cells. The interaction between OX40 and OX40L (OX40/OX40L) induces the expansion and proliferation of T cells and decreases the immunosuppression of regulatory T (Treg) cells to enhance the immune response to the specific antigen. For the important role OX40 takes in the process of immunity, many clinical trials are focusing on OX40 to find out whether it may have active effects in clinical cancer treatment. The results of clinical trials are still not enough. So, we reviewed the OX40 and its ligand (OX40L) function in cancer, clinical trials with OX40/OX40L and the correlation between OX40/OX40L and other immune checkpoints to add more ideas to tumor feasible treatment.


PROVIDER: S-EPMC6735535 | BioStudies | 2019-01-01


REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4621427 | BioStudies
2018-01-01 | S-EPMC5932227 | BioStudies
2020-01-01 | S-EPMC7049610 | BioStudies
1000-01-01 | S-EPMC3277294 | BioStudies
2018-01-01 | S-EPMC5797108 | BioStudies
2007-01-01 | S-EPMC1950941 | BioStudies
| S-EPMC3622718 | BioStudies
2014-01-01 | S-EPMC4294117 | BioStudies
2019-01-01 | S-EPMC6701347 | BioStudies
2015-01-01 | S-EPMC4570857 | BioStudies